Nordic Life Science
Pharma
Latest Pharma News
Orion Corporation has signed an agreement on the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division) to an investment fund managed by Axcel Management
The aim is to identify development opportunities both with Ygalo within the planned first indication, new indications and for the further development of Oncopeptides’ pipeline. Professor Paul G. Richardson, MD,
The international contract development and manufacturing organisation has been awarded the Queen’s Award 2018 for Enterprise, in the International Trade category. Cobra has a 20 year track record of supporting
The US Food and Drug Administration (FDA) has approved an update to the US prescribing information for Tresiba (insulin degludec) to include data from the DEVOTE trial. The DEVOTE trial
AstraZeneca and MedImmune has announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a
The company has entered an agreement with the United States Department of Defense (DoD) for the development of a prophylactic vaccine against the equine encephalitis virus-a rare, but potentially deadly
Clinical trials
The company provides an update on its clinical development programme, including updated guidance on expected milestones for the pivotal PARADIGME
The company announces informed consent signed by the first patient and enrolment process initiated in the clinical phase I/II trial
Affibody announces dosing of the first patients in a Phase II proof-of-concept study of ABY-035 in patients with moderate-to-severe psoriasis.
AstraZeneca and MedImmune announce an updated timeline for the final analysis of the Phase III MYSTIC trial of Imfinzi (durvalumab)
Bavarian Nordic announces a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb’s nivolumab
WntResearch announces that, after reviewing available research results and further consultations with experts in oncology and surgery, the company has
The company has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study
The company initiates a phase I/II clinical study in older adults with its quadrivalent nasal influenza vaccine candidate Immunose FLU.
AstraZeneca announces results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial. The results demonstrates a risk reduction
The company has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence a Phase IIa
Bavarian Nordic announces positive results from a Phase 3 pivotal study of its investigational, non-replicating smallpox vaccine, IMVAMUNE. The study
The company has completed the safety lead-in cohort and preliminary immune activation data in the phase I/II trial of ONCOS-102 in mesothelioma in combination with standard of care
The results from the SUSTAIN 7 trial, investigating the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg
AstraZeneca announces results from their Phase III KRONOS trial showing PT010 demonstrated a statistically significant improvement in eight out of
Swedish Orphan Biovitrum announces that the FDA has issued a Study may proceed letter for the first study in humans, thereby accepting
The US Food and Drug Administration has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Sirpa Jalkanen is a professor in the Academy of Finland, board member of Orion, and cofounder with her husband, Markku
Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula. While doing research for
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments